Clinical Trials Browser

Completed × Liver Neoplasms × spartalizumab × Clear all

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase 1/2 Completed

89 enrolled 37 charts

Gastrointestinal

Liver Neoplasms

NCT02947165 2022-01-31

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Phase 1 Completed

120 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02988440 2020-12-19

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

Phase 1 Completed

20 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Clinical Trials

IT-01

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients